With the CHMP affirmation, Moderna is on course to get EU approval for its fourth vaccine product and break new ground in ...

Boehringer Ingelheim has become the second company to get a product approved under the FDA's national priority voucher ...

The IPO, which saw 25 million shares sold at $16, in the middle of the $15 to $17 range predicted by the company, continues a ...

Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals ...

When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...

Released ahead of tomorrow's Rare Diseases Day, the report (PDF) says that people affected by rare conditions face "profound ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

Oxford-based Sitryx, which also has operations in Boston in the US, was founded in 2018 with seed funding from SV Health ...

Clinical trials are full of moving parts and, despite recent technological advances, they still come with manual processes ...

Reimbursement authority NICE has said that Incyte's JAK inhibitor cream Opzelura (ruxolitinib) can be used to treat people ...

35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 ...